A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision filed ...
DALLAS — A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk has asked ...
Small compounding pharmacies must halt selling copies immediately, larger facilities by March 19 Compounders argue FDA relied on Lilly for shortage figures Separate lawsuit by compounders over Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback